Breaking Finance News

Halozyme Therapeutics Down 16 Percent After Announcing Halt to Phase 2 Trial (HALO)

Halozyme Therapeutics (NASDAQ: HALO) announced Thursday that it was halting a Phase 2 study of Cinryze with recombinant human hyaluronidase due to unexpected, potentially serious antibody buildup. Although the antibodies have not been associated with adverse reactions, Halozyme, along with ViroPharma (NASDAQ: VPHM) have decided to conclude the trial.

“Given the profile of this clinical formulation and the time required to enable ViroPharma to move forward with this formulation, we support ViroPharma’s business decision,” said Gregory I. Frost, Ph.D., President and Chief Executive Officer, Halozyme.  “We have accumulated a robust data set regarding the clinical use of rHuPH20 across many different programs and indications, and feel confident about the safety profile of the rHuPH20 platform that has emerged from this clinical use and its continued application in our other products and programs around the world.”

[stock-tools exchange="NASDAQ" symbol="HALO" image_height="230" image_width="350"]

Disclosure: At the time of this writing, the author had no position in the company mentioned.

New to Breaking Finance News? Read about our format here.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.